Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
LFW Photonics Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Valneva SE - American Depositary Shares
(NQ:
VALN
)
6.720
-0.130 (-1.90%)
Streaming Delayed Price
Updated: 10:34 AM EDT, Sep 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Valneva SE - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Why Pfizer Stock Was so Healthy in August
↗
September 08, 2026
The beaten-down pharmaceutical stock was revived after it posted an estimates-beating quarter.
Via
The Motley Fool
Topics
Intellectual Property
Valneva (VALN) Q2 2026 Earnings Call Transcript
↗
August 20, 2026
Restructuring efforts and Lyme vaccine regulatory timeline take center stage.
Via
The Motley Fool
Topics
Earnings
Valneva Q2 Earnings Call Highlights
↗
August 13, 2026
Valneva (NASDAQ:VALN) reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and...
Via
MarketBeat
Topics
Earnings
Valneva Stock Tumbles 19% After FDA Suspension Of Ixchiq License In US, Wall Street Divided On The Impact
↗
August 25, 2025
Via
Stocktwits
Earnings Scheduled For May 7, 2025
↗
May 07, 2025
Via
Benzinga
Insights Ahead: Valneva's Quarterly Earnings
↗
May 06, 2025
Via
Benzinga
4 Analysts Have This To Say About Valneva
↗
February 19, 2025
Via
Benzinga
Valneva Q1 Earnings Call Highlights
↗
May 13, 2026
Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme...
Via
MarketBeat
Topics
Earnings
Why Wolfspeed Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
↗
September 30, 2025
Via
Benzinga
EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
August 26, 2025
Via
Benzinga
Crude Oil Surges 2%; Chicago Fed National Activity Index Edges Lower in July
↗
August 25, 2025
Via
Benzinga
Topics
Economy
12 Health Care Stocks Moving In Monday's Intraday Session
↗
August 25, 2025
Via
Benzinga
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
↗
August 25, 2025
Via
Benzinga
Safety Concerns Hit Valneva As Ixchiq Chikungunya Virus Vaccine Is Suspended In US
↗
August 25, 2025
Valneva shares fall after FDA suspends Ixchiq vaccine license citing new safety reports, raising questions over future U.S. sales and regulatory review.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
August 25, 2025
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 13, 2025
Via
Benzinga
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday
↗
July 23, 2025
Via
Benzinga
MP Materials, CoreWeave, Trade Desk And Other Big Stocks Moving Higher On Tuesday
↗
July 15, 2025
Via
Benzinga
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026
↗
June 05, 2025
Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set for early 2026.
Via
Benzinga
US Health Agencies Recommend Pausing Valneva's Chikungunya Vaccine For Older Adults After Adverse Events
↗
May 12, 2025
FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including deaths, trigger a new safety assessment.
Via
Benzinga
Topics
Death
12 Analysts Assess Valneva: What You Need To Know
↗
April 15, 2025
Via
Benzinga
Brazil Approves Valneva's Mosquito-Borne Chikungunya Vaccine
↗
April 14, 2025
Valneva's chikungunya vaccine Ixchiq receives Brazil approval, enabling expanded trials and access across Latin America and endemic regions.
Via
Benzinga
Lamb Weston Posts Better-Than-Expected Results, Joins Sanofi And Other Big Stocks Moving Higher On Thursday
↗
April 03, 2025
Via
Benzinga
Breaking Down Valneva: 6 Analysts Share Their Views
↗
March 21, 2025
Via
Benzinga
Earnings Scheduled For March 20, 2025
↗
March 20, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
January 31, 2025
Via
Benzinga
Valneva Vaccine Shows Sustained Immune Response In Adolescents One Year After Single Shot
↗
January 21, 2025
Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.
Via
Benzinga
Accenture Posts Upbeat Results, Joins Darden Restaurants, CarMax And Other Big Stocks Moving Higher On Thursday
↗
December 19, 2024
Via
Benzinga
Valneva's Chikungunya Shot Shows Strong, Long-Lasting Antibody Persistence At Three Years, Comparable In Older And Younger Adults
↗
December 03, 2024
Valneva reports long-lasting antibody persistence in its chikungunya vaccine three years post-dose, supporting its global approvals and expansion efforts.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
